Article

Do Citrus Fruits Impact Risk of Melanoma?

The impact of products such as orange juice on melanoma.

The impact of products such as orange juice on melanoma.

Individuals who regularly consume orange juice or grapefruit may have a higher risk of developing melanoma, according to research recently published online in the Journal of Clinical Oncology.

Citrus products are rich in psoralens and furocoumarins, a group of naturally occurring chemicals known to potentially possess photocarcinogenic properties.

To evaluate the hypothesized risk of cutaneous malignant melanoma linked to citrus consumption, Abrar Qureshi, MD, MPH, dermatology chair at Brown University and a practicing dermatologist at Rhode Island Hospital, and colleagues evaluated data from a total of 105,432 adults who participated in the Nurses' Health Study and the Health Professionals Follow-Up Study. Every 2 to 4 years, the study participants were required to complete health and lifestyle related surveys.

According to the results, 1,840 people developed melanoma over 24-26 years of follow-up. Participants who consumed orange juice at least once a day were approximately 25% more likely to develop the skin cancer.

Similarly, individuals who ate one serving of grapefruit at least three times a week had a 41% higher risk of developing melanoma.

Interestingly, researchers have yet to pinpoint a correlation between melanoma risk and consuming or drinking whole oranges or grapefruit juice.

Qureshi noted that the photoactive psoralens and furocoumarins contained in citrus foods make the skin more sensitive to the sun. In any case, further studies are necessary to understand the findings and explore implications for the future.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards